0000950170-22-014827 | 10-Q | XBRL Viewer

Label

Element

Value

Other Risks And Uncertainties Policy [Text Block]

grts_OtherRisksAndUncertaintiesPolicyTextBlock

Other Risks and Uncertainties

The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.

In March 2020, the World Health Organization declared the global novel coronavirus disease (“COVID-19”) outbreak a pandemic. To date, the Company’s business has not been materially impacted by the COVID-19 pandemic. However, the Company has experienced slowing of patient recruitment and sample collection in its ongoing clinical trials and cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected.

Contract With Customer Liability Addition

grts_ContractWithCustomerLiabilityAddition

$ 0

Contract With Customer Liability Addition

grts_ContractWithCustomerLiabilityAddition

122,000

Contract With Customer Liability Addition

grts_ContractWithCustomerLiabilityAddition

2,698,000

Contract With Customer Liability Addition

grts_ContractWithCustomerLiabilityAddition

Receivables Gross

grts_ReceivablesGross

Receivables Gross

grts_ReceivablesGross

Receivables Gross

grts_ReceivablesGross

500,000

Receivables Gross

grts_ReceivablesGross

700,000

Maximum Aggregate Contingent Milestone Payment

grts_MaximumAggregateContingentMilestonePayment

685,000,000.0

Deferred Contract Acquisition Costs

grts_DeferredContractAcquisitionCosts

$ 0

Issuance of common stock for warrant exercises, Share

grts_IssuanceOfCommonStockForWarrantExercisesShare

3,442,567

Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants

grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants

$ (451,000)

Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants

grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants

(451,000)

Stock Issued During Period Value Purchase Agreement

grts_StockIssuedDuringPeriodValuePurchaseAgreement

20,839,000

Stock Issued During Period Value Purchase Agreement

grts_StockIssuedDuringPeriodValuePurchaseAgreement

$ 20,839,000

Schedule Of Supplemental Information Related To Leases Table [Text Block]

grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock

Supplemental information related to leases was as follows:


	Six Months Ended June 30,
	2022			2021
Cash paid for amounts included in the measurement of lease liabilities (in thousands):
Operating cash flows from operating leases	$	4,193		$	3,922
New right-of-use assets obtained in exchange for lease obligations (in thousands):
Operating leases	$	781		$	109
Weighted-average remaining lease term (years):
Operating leases		5.1			6.0
Weighted-average discount rate:
Operating leases		7.4	%		9.0	%

Lessee Operating Lease Liability Payments Due After Year Four

grts_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour

$ 62,813,000

Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year

grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear

2025-04

Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year

grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear

2023-06

Noncash Operating Lease Expense

grts_NoncashOperatingLeaseExpense

$ 4,655,000

Noncash Operating Lease Expense

grts_NoncashOperatingLeaseExpense

3,822,000

Non Refundable Option Fee

grts_NonRefundableOptionFee

$ 40,000,000.0

Percentage Of Proceeds Payable As Compensation To Underwriter

grts_PercentageOfProceedsPayableAsCompensationToUnderwriter

3.00%

Percentage Of Proceeds Payable As Compensation To Underwriter

grts_PercentageOfProceedsPayableAsCompensationToUnderwriter

3.00%

Cash Cash Equivalents And Marketable Securities

grts_CashCashEquivalentsAndMarketableSecurities

$ 144,600,000

Long-term marketable securities

grts_LongTermMarketableSecurities

Long-term marketable securities

grts_LongTermMarketableSecurities

4,617,000

Operating lease payment under the boston lease

grts_OperatingLeasePaymentUnderTheBostonLease

79,113,000

Maximum Milestone Consideration Payable

grts_MaximumMilestoneConsiderationPayable

123,500,000

Contract With Customer Liability Deductions

grts_ContractWithCustomerLiabilityDeductions

6,294,000

Contract With Customer Liability Deductions

grts_ContractWithCustomerLiabilityDeductions

Contract With Customer Liability Deductions

grts_ContractWithCustomerLiabilityDeductions

4,857,000

Contract With Customer Liability Deductions

grts_ContractWithCustomerLiabilityDeductions

530,000

Maximum Offering Expenses Agreed To Be Reimbursed

grts_MaximumOfferingExpensesAgreedToBeReimbursed

50,000

Maximum Offering Expenses Agreed To Be Reimbursed

grts_MaximumOfferingExpensesAgreedToBeReimbursed

50,000

Proceeds From Non Refundable Upfront Payment

grts_ProceedsFromNonRefundableUpfrontPayment

20,000,000.0

Proceeds From Non Refundable Upfront Payment

grts_ProceedsFromNonRefundableUpfrontPayment

20,000,000.0

Proceeds From Non Refundable Upfront Payment

grts_ProceedsFromNonRefundableUpfrontPayment

30,000,000.0

Proceeds From Non Refundable Upfront Payment

grts_ProceedsFromNonRefundableUpfrontPayment

2,200,000

Maximum Securities Covered Under Registration Agreement

grts_MaximumSecuritiesCoveredUnderRegistrationAgreement

250,000,000.0

Maximum Securities Covered Under Registration Agreement

grts_MaximumSecuritiesCoveredUnderRegistrationAgreement

250,000,000.0

Future Funding Expected

grts_FutureFundingExpected

1,000,000.0

Maximum Milestone Payment Obligation

grts_MaximumMilestonePaymentObligation

36,400,000

Maximum Milestone Payment Obligation

grts_MaximumMilestonePaymentObligation

$ 34,800,000

Warrants To Purchase Shares Of Common Stock

grts_WarrantsToPurchaseSharesOfCommonStock

27,480,719

Contract With Customer Liability Revenue Recognized Including New Contracts In Period